| Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes E Bernard, Y Nannya, RP Hasserjian, SM Devlin, H Tuechler, ... Nature medicine 26 (10), 1549-1556, 2020 | 557 | 2020 |
| Inherited and somatic defects in DDX41 in myeloid neoplasms C Polprasert, I Schulze, MA Sekeres, H Makishima, B Przychodzen, ... Cancer cell 27 (5), 658-670, 2015 | 485 | 2015 |
| Germ line DDX41 mutations define a unique subtype of myeloid neoplasms H Makishima, R Saiki, Y Nannya, S Korotev, C Gurnari, J Takeda, ... Blood 141 (5), 534-549, 2023 | 110 | 2023 |
| Frequent germline mutations of HAVCR2 in sporadic subcutaneous panniculitis-like T-cell lymphoma C Polprasert, Y Takeuchi, N Kakiuchi, K Yoshida, T Assanasen, W Sitthi, ... Blood advances 3 (4), 588-595, 2019 | 98 | 2019 |
| Angioimmunoblastic T-cell lymphomas with the RHOA p. Gly17Val mutation have classic clinical and pathologic features SL Ondrejka, B Grzywacz, J Bodo, H Makishima, C Polprasert, JW Said, ... The American journal of surgical pathology 40 (3), 335-341, 2016 | 65 | 2016 |
| Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3 … JP Laubach, F Schjesvold, M Mariz, MA Dimopoulos, E Lech-Maranda, ... The Lancet Oncology 22 (1), 142-154, 2021 | 56 | 2021 |
| Recurrent genetic defects on chromosome 5q in myeloid neoplasms N Hosono, H Makishima, R Mahfouz, B Przychodzen, K Yoshida, A Jerez, ... Oncotarget 8 (4), 6483, 2016 | 50 | 2016 |
| Molecular predictors of response in patients with myeloid neoplasms treated with lenalidomide E Negoro, T Radivoyevitch, C Polprasert, V Adema, N Hosono, ... Leukemia 30 (12), 2405-2409, 2016 | 43 | 2016 |
| BRCC3 mutations in myeloid neoplasms D Huang, Y Nagata, V Grossmann, T Radivoyevitch, Y Okuno, G Nagae, ... Haematologica 100 (8), 1051, 2015 | 35 | 2015 |
| Novel DDX41 variants in Thai patients with myeloid neoplasms C Polprasert, J Takeda, P Niparuck, T Rattanathammethee, A Pirunsarn, ... International Journal of Hematology 111, 241-246, 2020 | 30 | 2020 |
| Programmed cell death 1 and programmed cell death ligands in extranodal natural killer/T cell lymphoma: expression pattern and potential prognostic relevance H Muhamad, N Suksawai, T Assanasen, C Polprasert, U Bunworasate, ... Acta Haematologica 143 (1), 78-88, 2020 | 26 | 2020 |
| TP53 state dictates genome stability, clinical presentation and outcomes in myelodysplastic syndromes E Bernard, Y Nannya, T Yoshizato, RP Hasserjian, R Saiki, Y Shiozawa, ... Blood 134, 675, 2019 | 23 | 2019 |
| Factors associated with erythropoiesis-stimulating agent hyporesponsiveness anemia in chronic kidney disease patients K Amnuay, N Srisawat, K Wudhikarn, T Assanasen, C Polprasert Hematology Reports 11 (3), 8183, 2019 | 18 | 2019 |
| Case report: severe CMV colitis in a patient with follicular lymphoma after chemotherapy C Polprasert, C Wongjitrat, N Wisedopas Journal of the Medical Association of Thailand 94 (4), 498, 2011 | 17 | 2011 |
| Levofloxacin-induced severe thrombocytopenia C Polprasert, K Prayongratana J Med Assoc Thai 92 (Suppl 3), S69-71, 2009 | 17 | 2009 |
| Germline HAVCR2 mutations and their relation to the clinical spectrum of subcutaneous panniculitis-like T-cell lymphoma and hemophagocytic lymphohistiocytosis: results from a … C Moonla, C Polprasert, P Komvilaisak, T Rattanathammethee, ... Haematologica 108 (10), 2743, 2023 | 15 | 2023 |
| A randomized multicenter trial comparing low-dose prednisolone versus observation for prevention of recurrences in adult immune thrombocytopenia A Pirunsarn, P Kijrattanakul, S Chamnanchanunt, C Polprasert, ... Clinical and Applied Thrombosis/Hemostasis 24 (6), 867-873, 2018 | 15 | 2018 |
| Frequent mutations in HLA and related genes in extranodal NK/T cell lymphomas C Polprasert, Y Takeuchi, H Makishima, K Wudhikarn, N Kakiuchi, ... Leukemia & Lymphoma 62 (1), 95-103, 2021 | 14 | 2021 |
| A novel genetic and morphologic phenotype of ARID2-mediated myelodysplasia H Sakai, N Hosono, H Nakazawa, B Przychodzen, C Polprasert, ... Leukemia 32 (3), 839-843, 2018 | 14 | 2018 |
| Low cost combination of DCIP and MCV was better than that of DCIP and OF in the screening for hemoglobin E K Prayongratana, C Polprasert, K Raungrongmorakot, K Tatone, ... Medical journal of the Medical Association of Thailand 91 (10), 1499, 2008 | 14 | 2008 |